Genoway (France) Today
| ALGEN Stock | EUR 2.48 0.05 1.98% |
PerformanceMild
| Odds Of DistressTiny
|
Genoway is selling at 2.48 as of the 12th of February 2026; that is 1.98% down since the beginning of the trading day. The stock's last reported lowest price was 2.39. Genoway has a very small chance of experiencing financial distress in the next few years but had a somewhat mild performance during the last 90 days. The performance scores are derived for the period starting the 14th of November 2025 and ending today, the 12th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of May 2007 | Category Healthcare | Classification Health Care |
genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company was founded in 1999 and is based in Lyon, France. GENOWAY operates under Biotechnology classification in France and is traded on Paris Stock Exchange. The company has 12.34 M outstanding shares. More on Genoway
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Genoway Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Genoway's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Genoway or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman of the Board and CEO | Alexandre Fraichard | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Genoway's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Genoway's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsDebt leverage enables Genoway to amplify potential investment gains using borrowed funds. Evaluating debt relative to total assets helps investors assess Genoway's financial structure and understand the extent to which Genoway's operations depend on creditor capital.
| |||||
Genoway (ALGEN) is traded on Euronext Paris in France and employs 1 people. Genoway is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 31.22 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genoway's market, we take the total number of its shares issued and multiply it by Genoway's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genoway operates under Biotechnology sector and is part of Health Care industry. The entity has 12.34 M outstanding shares.
Genoway has accumulated about 0 in cash with 5.38 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.52.
Check Genoway Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Genoway is €31.22 Million. Genoway retains 7.75 (percent) of its outstanding shares held by insiders and 15.78 (percent) owned by outside corporations. Note, that even with substantial debt, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.
Check Genoway Ownership Details
Genoway Historical Income Statement
Genoway Stock Against Markets
Genoway Stock Analysis Notes
About 16.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.62. Some equities with similar Price to Book (P/B) outperform the market in the long run. Genoway had not issued any dividends in recent years. genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company was founded in 1999 and is based in Lyon, France. GENOWAY operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 105 people. For more info on Genoway please contact Alexandre Fraichard at 33 4 37 65 41 00 or go to https://www.genoway.com.Genoway Quarterly Total Revenue |
|
Genoway Investment Alerts
| Genoway had very high historical volatility over the last 90 days | |
| Genoway is unlikely to experience financial distress in the next 2 years |
Genoway Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 31.22 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genoway's market, we take the total number of its shares issued and multiply it by Genoway's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Genoway Profitablity
Genoway's profitability indicators refer to fundamental financial ratios that showcase Genoway's ability to generate income relative to its revenue or operating costs. If, let's say, Genoway is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Genoway's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Genoway's profitability requires more research than a typical breakdown of Genoway's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.05 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. | Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.06 | 0.07 | |
| Return On Capital Employed | 0.09 | 0.09 | |
| Return On Assets | 0.05 | 0.05 | |
| Return On Equity | 0.11 | 0.12 |
Management Efficiency
Genoway has return on total asset (ROA) of 0.0136 % which means that it generated a profit of $0.0136 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0712 %, meaning that it generated $0.0712 on every $100 dollars invested by stockholders. Genoway's management efficiency ratios could be used to measure how well Genoway manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/12/2026, Return On Tangible Assets is likely to grow to 0.07. Also, Return On Capital Employed is likely to grow to 0.09. As of 02/12/2026, Total Current Liabilities is likely to drop to about 6.3 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 20.6 M| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.76 | 0.94 | |
| Tangible Book Value Per Share | 1.21 | 0.69 | |
| Enterprise Value Over EBITDA | 8.36 | 10.18 | |
| Price Book Value Ratio | 2.20 | 2.56 | |
| Enterprise Value Multiple | 8.36 | 10.18 | |
| Price Fair Value | 2.20 | 2.56 | |
| Enterprise Value | 32.6 M | 34.2 M |
Leadership effectiveness at Genoway is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 12th of February 2026, Genoway retains the Risk Adjusted Performance of 0.0278, downside deviation of 2.39, and Market Risk Adjusted Performance of (0.08). Genoway technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Genoway Price Movement Analysis
Transformation |
The output start index for this execution was zero with a total number of output elements of sixty-one. Genoway Tanh Of Price Series is a hyperbolic price transformation function.
Genoway Outstanding Bonds
Genoway issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Genoway uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Genoway bonds can be classified according to their maturity, which is the date when Genoway has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Genoway Predictive Daily Indicators
Genoway intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Genoway stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 1348.38 | |||
| Daily Balance Of Power | (0.19) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 2.53 | |||
| Day Typical Price | 2.51 | |||
| Price Action Indicator | (0.07) | |||
| Period Momentum Indicator | (0.05) |
Genoway Forecast Models
Genoway's time-series forecasting models are one of many Genoway's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genoway's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Be your own money manager
Our tools can tell you how much better you can do entering a position in Genoway without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Additional Tools for Genoway Stock Analysis
When running Genoway's price analysis, check to measure Genoway's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genoway is operating at the current time. Most of Genoway's value examination focuses on studying past and present price action to predict the probability of Genoway's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genoway's price. Additionally, you may evaluate how the addition of Genoway to your portfolios can decrease your overall portfolio volatility.